Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc, dated August 7, 2024, reports a specific corporate action regarding the company's share buyback programme. Haleon is a global leader in consumer health with a portfolio spanning Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals and Supplements (VMS).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on a share repurchase transaction.
| Metric | Value |
|---|---|
| Shares Purchased | 701,000 |
| Highest Price Paid | 372.80 pence |
| Lowest Price Paid | 366.90 pence |
| Volume Weighted Average Price | 370.3950 pence |
| Registered Share Capital Post-Transaction | 9,129,806,715 ordinary shares |
Material Changes
The primary material change is the reduction of the company's registered share capital following the cancellation of 701,000 ordinary shares purchased under the Buyback Programme announced on August 1, 2024.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It serves strictly as a regulatory disclosure of the share transaction in accordance with the Market Abuse Regulation.
Key Facts for Investor Verification
- Verify the total number of shares repurchased to date under the August 1, 2024 Buyback Programme.
- Confirm the updated total share count of 9,129,806,715 for disclosure threshold calculations under FCA rules.
- Review the full trade breakdown available via the provided London Stock Exchange link for granular transaction data.